Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHANNA CONTRERAS

Allopathic & Osteopathic Physicians Internal Medicine Advanced Heart Failure and Transplant Cardiology

NPI
1528188190
CMS profile
113985
Location
NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$70,703.26

193 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 4; records 51–100 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHANNA CONTRERAS

NPI 1528188190 · CMS profile ID 113985

Allopathic & Osteopathic Physicians / Internal Medicine / Advanced Heart Failure and Transplant Cardiology

NEW YORK, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 4; records 51–100 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1528188190?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHANNA CONTRERAS, NPI 1528188190, CMS profile ID 113985. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1528188190?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). JOHANNA CONTRERAS, NPI 1528188190, CMS profile ID 113985. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 4; records 51–100 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1528188190?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
JOHANNA CONTRERAS, NPI 1528188190, CMS profile ID 113985, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 4; records 51–100 of 193 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1528188190?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

193 matching records · $70,703.26 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 193 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 193.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Bayer HealthCare Pharmaceuticals Inc. $19.1410/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 789140993 CMS
CVRx, Inc. $92.1510/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851084023 CMS
CVRx, Inc. $125.0010/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851084027 CMS
Esperion Therapeutics, Inc. $27.2709/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838269521 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $27.7909/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763545028 CMS
Esperion Therapeutics, Inc. $20.8109/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838269515 CMS
Novo Nordisk Inc $16.5609/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 811045653 CMS
Novartis Pharmaceuticals Corporation $16.0809/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812644009 CMS
AstraZeneca Pharmaceuticals LP $1,075.0009/20/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830082541 CMS
Amgen Inc. $5.0909/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825426031 CMS
Novartis Pharmaceuticals Corporation $20.5409/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812644007 CMS
Lilly USA, LLC $1,425.0009/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819181763 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $324.9709/11/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763545062 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $111.7509/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763545030 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.1609/10/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763545054 CMS
Eli Lilly and Company $2,375.0009/03/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818569093 CMS
Novartis Pharmaceuticals Corporation $16.2809/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812644005 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $704.0008/31/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763545052 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $289.7608/31/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763545058 CMS
Merck Sharp & Dohme Corporation $18.4208/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848674379 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.8108/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763545032 CMS
Janssen Pharmaceuticals, Inc $31.9808/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788351099 CMS
Amgen Inc. $14.0308/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825426025 CMS
AstraZeneca Pharmaceuticals LP $2,150.0008/25/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829568167 CMS
AstraZeneca Pharmaceuticals LP $125.0008/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829744117 CMS
BIOTRONIK INC. $176.9208/21/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843851711 CMS
BIOTRONIK INC. $161.0608/20/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843851705 CMS
Novartis Pharmaceuticals Corporation $9.0908/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812644003 CMS
Abbott Laboratories $153.6608/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833732327 CMS
Abbott Laboratories $133.0008/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833732323 CMS
Amgen Inc. $16.2608/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826533207 CMS
AstraZeneca Pharmaceuticals LP $116.0308/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829831513 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $22.9208/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763545034 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $124.6308/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763545026 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $7.0808/03/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763545048 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $28.2608/03/2021 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763545050 CMS
CVRx, Inc. $186.3708/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 851084019 CMS
AstraZeneca Pharmaceuticals LP $16.4907/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829936493 CMS
Novartis Pharmaceuticals Corporation $11.9407/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812644001 CMS
Bardy Diagnostics, Inc. $88.8207/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 854977503 CMS
Amgen Inc. $15.7407/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825426019 CMS
Esperion Therapeutics, Inc. $28.9707/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838269511 CMS
Abbott Laboratories $123.7107/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833734367 CMS
Abbott Laboratories $20.0107/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833734437 CMS
Esperion Therapeutics, Inc. $7.6607/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838269509 CMS
Novartis Pharmaceuticals Corporation $9.6407/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 812643999 CMS
Abbott Laboratories $24.9207/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833734109 CMS
Abbott Laboratories $117.1507/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833732333 CMS
BOSTON SCIENTIFIC CORPORATION $96.0207/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777611991 CMS
AstraZeneca Pharmaceuticals LP $2,150.0006/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829550809 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $57,138.78 158
PY2020 $76,539.57 133
PY2021 $70,703.26 193
PY2022 $89,429.09 227
PY2023 $97,525.56 246
PY2024 $109,865.69 206
PY2025 $32,381.17 154

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $338,969.19 124
PY2024 Recipient $1,557.90 3
PY2024 Principal investigator $75,945.51 12
PY2023 Principal investigator $109,151.54 16
PY2022 Principal investigator $133,670.04 10
PY2021 Principal investigator $25,164.14 23
PY2020 Recipient $300.00 1
PY2020 Principal investigator $52,760.80 38
PY2019 Principal investigator $110,137.20 16

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

124 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Boehringer Ingelheim International GmbH $54.00 12/25/2025 Non-covered Recipient Entity
Mount Sinai West
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220675778
Principal investigator 1 Boehringer Ingelheim International GmbH $4.35 12/25/2025 Non-covered Recipient Entity
Mount Sinai West
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220675780
Principal investigator 1 Boehringer Ingelheim International GmbH $21.75 12/25/2025 Non-covered Recipient Entity
Mount Sinai West
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220675782
Principal investigator 1 Boehringer Ingelheim International GmbH $2,747.00 12/15/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761261
Principal investigator 1 Boehringer Ingelheim International GmbH $2,747.00 12/15/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761263
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 12/09/2025 Non-covered Recipient Entity
Mount Sinai West
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220996192
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 12/03/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220998112
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761257
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761259
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,007.72 11/20/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220998110
Principal investigator 1 Boehringer Ingelheim International GmbH $4,514.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761213
Principal investigator 1 Boehringer Ingelheim International GmbH $4,514.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761215
Principal investigator 1 Boehringer Ingelheim International GmbH $4,514.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761217
Principal investigator 1 Boehringer Ingelheim International GmbH $4,514.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761219
Principal investigator 1 Boehringer Ingelheim International GmbH $4,514.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761221
Principal investigator 1 Boehringer Ingelheim International GmbH $4,514.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761223
Principal investigator 1 Boehringer Ingelheim International GmbH $4,514.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761225
Principal investigator 1 Boehringer Ingelheim International GmbH $4,514.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761227
Principal investigator 1 Boehringer Ingelheim International GmbH $3,711.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761229
Principal investigator 1 Boehringer Ingelheim International GmbH $3,711.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761231
Principal investigator 1 Boehringer Ingelheim International GmbH $3,711.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761233
Principal investigator 1 Boehringer Ingelheim International GmbH $3,711.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761235
Principal investigator 1 Boehringer Ingelheim International GmbH $3,711.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761237
Principal investigator 1 Boehringer Ingelheim International GmbH $3,711.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761239
Principal investigator 1 Boehringer Ingelheim International GmbH $2,747.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761241
Principal investigator 1 Boehringer Ingelheim International GmbH $2,747.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761243
Principal investigator 1 Boehringer Ingelheim International GmbH $2,747.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761245
Principal investigator 1 Boehringer Ingelheim International GmbH $2,747.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761247
Principal investigator 1 Boehringer Ingelheim International GmbH $3,610.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761249
Principal investigator 1 Boehringer Ingelheim International GmbH $3,610.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761251
Principal investigator 1 Boehringer Ingelheim International GmbH $3,610.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761253
Principal investigator 1 Boehringer Ingelheim International GmbH $463.00 11/19/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761255
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,007.72 11/11/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220998108
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761209
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761211
Principal investigator 1 Boehringer Ingelheim International GmbH $34.98 10/27/2025 Non-covered Recipient Entity
Mount Sinai West
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220675784
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 10/27/2025 Non-covered Recipient Entity
Mount Sinai West
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220675786
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 10/27/2025 Non-covered Recipient Entity
Mount Sinai West
EASi-HF Reduced A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40% No dispute reported 06/30/2026 1220675788
Principal investigator 1 Boehringer Ingelheim International GmbH $99.90 10/27/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761265
Principal investigator 1 Boehringer Ingelheim International GmbH $4,587.00 10/20/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761201
Principal investigator 1 Boehringer Ingelheim International GmbH $389.00 10/20/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761203
Principal investigator 1 Boehringer Ingelheim International GmbH $3,309.00 10/20/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761205
Principal investigator 1 Boehringer Ingelheim International GmbH $3,638.00 10/20/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761207
Principal investigator 1 Boehringer Ingelheim International GmbH $4,587.00 10/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761193
Principal investigator 1 Boehringer Ingelheim International GmbH $4,587.00 10/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761195
Principal investigator 1 Boehringer Ingelheim International GmbH $3,638.00 10/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761197
Principal investigator 1 Boehringer Ingelheim International GmbH $2,680.00 10/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761199
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $8,346.20 10/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220998106
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761189
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761191
Principal investigator 1 Boehringer Ingelheim International GmbH $59.94 09/24/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761187
Principal investigator 1 Genentech, Inc. $1,020.00 09/23/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1211580120
Principal investigator 1 Amgen Inc. $4,879.81 09/09/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Maridebart Cafraglutide on Mortality and Morbidity in Participants Living With Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (MARITIME-HF) No dispute reported 06/30/2026 1246642439
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761157
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761159
Principal investigator 1 Boehringer Ingelheim International GmbH $109.50 08/26/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761181
Principal investigator 1 Boehringer Ingelheim International GmbH $2.61 08/26/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761183
Principal investigator 1 Boehringer Ingelheim International GmbH $2.82 08/26/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761185
Principal investigator 1 Boehringer Ingelheim International GmbH $4,587.00 08/20/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761165
Principal investigator 1 Boehringer Ingelheim International GmbH $3,309.00 08/20/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761167
Principal investigator 1 Boehringer Ingelheim International GmbH $3,638.00 08/20/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761169
Principal investigator 1 Boehringer Ingelheim International GmbH $2,680.00 08/20/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761171
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $5,007.72 08/15/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220998104
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761153
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761155
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,012.50 07/28/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Dapagliflozin in Acute Decompensated Heart Failure No dispute reported 06/30/2026 1185543072
Principal investigator 1 Boehringer Ingelheim International GmbH $219.78 07/28/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761173
Principal investigator 1 Boehringer Ingelheim International GmbH $219.00 07/28/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761175
Principal investigator 1 Boehringer Ingelheim International GmbH $1.74 07/28/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761177
Principal investigator 1 Boehringer Ingelheim International GmbH $5.64 07/28/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761179
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $24,801.00 07/09/2025 Non-covered Recipient Entity
Mount Sinai School of Medicine
SONATA-HCM / Sotagliflozin / LX4211 No dispute reported 06/30/2026 1248066759
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761161
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761163
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,338.48 06/26/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220998102
Principal investigator 1 Boehringer Ingelheim International GmbH $93.28 06/24/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761145
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 06/24/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761147
Principal investigator 1 Boehringer Ingelheim International GmbH $6.96 06/24/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761149
Principal investigator 1 Boehringer Ingelheim International GmbH $3.76 06/24/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761151
Principal investigator 1 Genentech, Inc. $750.00 06/23/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1211580045
Principal investigator 1 Boehringer Ingelheim International GmbH $2,680.00 06/20/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761139
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $11,240.00 06/06/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine
A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) (DISCOVER-HCM) No dispute reported 06/30/2026 1235995613
Principal investigator 1 Boehringer Ingelheim International GmbH $4,587.00 06/04/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761135
Principal investigator 1 Boehringer Ingelheim International GmbH $3,638.00 06/04/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761137
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761131
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761133
Principal investigator 1 Boehringer Ingelheim International GmbH $319.68 05/27/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761143
Principal investigator 1 Boehringer Ingelheim International GmbH $2,228.00 05/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761109
Principal investigator 1 Boehringer Ingelheim International GmbH $3,713.00 05/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761111
Principal investigator 1 Boehringer Ingelheim International GmbH $1,430.00 05/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761113
Principal investigator 1 Boehringer Ingelheim International GmbH $1,350.00 05/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761115
Principal investigator 1 Boehringer Ingelheim International GmbH $2,430.00 05/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761117
Principal investigator 1 Boehringer Ingelheim International GmbH $1,350.00 05/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761119
Principal investigator 1 Boehringer Ingelheim International GmbH $18,500.00 05/16/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761121
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $1,669.24 05/09/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220998100
Principal investigator 1 Boehringer Ingelheim International GmbH $425.00 05/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761123
Principal investigator 1 Boehringer Ingelheim International GmbH $750.00 05/02/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761125
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761127
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761129
Principal investigator 1 Boehringer Ingelheim International GmbH $1.55 04/23/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761141
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761105
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761107
Principal investigator 1 Boehringer Ingelheim International GmbH $79.92 03/25/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761103
Principal investigator 1 Genentech, Inc. $3,502.00 03/24/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1211580036
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $6,676.96 03/13/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220998098
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761085
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761087
Principal investigator 1 Genentech, Inc. $675.00 02/19/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1211580032
Principal investigator 1 Genentech, Inc. $3,181.20 02/19/2025 Non-covered Recipient Entity
BIOMEDICAL RESEARCH ALLIANCE OF NEW YORK
Phase 1c Selnoflast Proof of Concept No dispute reported 06/30/2026 1211580040
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761081
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761083
Principal investigator 1 Boehringer Ingelheim International GmbH $432.00 01/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761089
Principal investigator 1 Boehringer Ingelheim International GmbH $432.00 01/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761091
Principal investigator 1 Boehringer Ingelheim International GmbH $432.00 01/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761093
Principal investigator 1 Boehringer Ingelheim International GmbH $432.00 01/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761095
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 01/31/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761097
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,362.04 01/27/2025 Non-covered Recipient Entity
Mount Sinai West
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy No dispute reported 06/30/2026 1235995569
Principal investigator 1 ENDOTRONIX, INC. $22,573.80 01/24/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
PROACTIVE-HF2 No dispute reported 06/30/2026 1254601439
Principal investigator 1 AstraZeneca Pharmaceuticals LP $348.85 01/22/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
This is a randomised double blind placebo controlled multi center sequential phase 2b and Phase 3 study to evaluate the efficacy and safety of AZD4831 administered for up to 48 Weeks in participants with heart failure with left ventricular ejection fractio No dispute reported 06/30/2026 1185543076
Principal investigator 1 AstraZeneca Pharmaceuticals LP $24,127.00 01/17/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
Tracking treatment pathways in adult patients with hyperkalemia (TRACK) No dispute reported 06/30/2026 1185543074
Principal investigator 1 Boehringer Ingelheim International GmbH $12.00 01/14/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761101
Principal investigator 1 Boehringer Ingelheim International GmbH $12.00 01/08/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761099
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $18,876.21 01/06/2025 Non-covered Recipient Entity
Icahn School Of Medicine At Mount Sinai
A Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate Mavacamten in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy No dispute reported 06/30/2026 1235996797
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761077
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Covered Recipient Teaching Hospital
Mount Sinai Hospital
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220761079